Orchid Pharma Limited

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about the appointment of a cost auditor and change in designation of a Director, Mr. Arjun Dhanuka, to Whole-Time Director.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026, where the Board of Directors approved the appointment of Cost Auditors for FY 2026-27, appointment of Mr. Arjun Dhanuka as Whole-Time Director, and other matters.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about the transcript of Analysts/ Investors Earning Call held with Public at large on August 21, 2026, on the financial performance/ financial results of the Company for the Quarter-I of Financial Year 2026-27, ended on June 30, 2026.

Orchid Pharma Limited

Orchid Pharma Limited has uploaded the audio recording of its analysts/investors earnings call on its website, discussing unaudited Q1 FY 2026-27 financial results.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about Presentation for Investors, including financial performance for the Quarter-I of Financial Year 2026-27, ended on June 30, 2026.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about the schedule of an Analysts/Investors Earning Call hosted by 'Systematix Institutional Equities' to discuss the financial results/ performance of the Company for the Quarter-I ended on June 30, 2026.

Orchid Pharma Limited

Orchid Pharma Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, in relation to the Qualified Institutional Placement (QIP) of Rs. 400 crores. The report states that there are no deviations from the objects of the issue and the utilization of the issue proceeds is as per the disclosures in the statements.

Orchid Pharma Limited

Orchid Pharma Limited has submitted its revised audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, following the sanctioned scheme of amalgamation and arrangement of Dhanuka Laboratories Limited with Orchid Pharma Limited.

Orchid Pharma Limited

Orchid Pharma Limited has submitted its financial results for the period ended June 30, 2026, to the NSE.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding allotment of 44,586,052 securities pursuant to Scheme of Arrangement/Amalgamation at its meeting held on August 01, 2026.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on August 01, 2026. The Board of Directors approved the issuance and allotment of 4,45,86,052 fully paid up equity shares of Rs. 10 each to the eligible shareholders of Dhanuka Laboratories Limited as on record date July 23, 2026, pursuant to the scheme of Amalgamation.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding 'Intimation regarding investor roadshow ' to be held in Singapore on July 29-31, 2026.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the compliances required under the above said regulation.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange that the Record date for the purpose of Merger/HiveOff is 23-Jul-2026.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company, including the effectiveness of the Scheme, alteration of capital clause, fixing of record date, and share exchange ratio.

Orchid Pharma Limited

Orchid Pharma Limited has announced the outcome of its board meeting, noting the effectiveness of the scheme of amalgamation with Dhanuka Laboratories Limited, effective July 10, 2026. The company's authorized share capital has increased, and the record date for determining shareholders eligible for shares in the amalgamated company has been set as July 23, 2026.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited and their respective shareholders and creditors under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Orchid Pharma Limited

Orchid Pharma Limited has entered into a licensing and supply agreement with Pharmasyntez JSC, Russia, for the commercialization of Exblifep (Cefepime/Enmetazobactam) in Russia, a novel combination antibiotic for the treatment of complicated urinary tract infections and hospital-acquired and ventilator-associated bacterial pneumonia.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.